Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.
Share
Why It Matters
A big stock expert started watching Eloxx Pharma and says it looks good. This means the company might have promising things coming up that people should pay attention to.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.